Olga Kulemina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Olga Kulemina has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Nadezhda Shnalieva
VA Almazov National Medical Research Center, 2 Akkuratova ul., Saint Petersburg, Russian Federation, 197341
7 shared publications - Natalia Lazorko
VA Almazov National Medical Research Center, 2 Akkuratova ul., Saint Petersburg, Russian Federation, 197341
5 shared publications - E. G. Lomaia
VA Almazov National Medical Research Center, 2 Akkuratova ul., Saint Petersburg, Russian Federation, 197341
4 shared publications Elza Lomaia
4 shared publicationsTamara Chitanava
Almazov National Medical Research Centre, St. Petersburg, Russian Federation
4 shared publications- E. I. Sbityakova
VA Almazov National Medical Research Center, 2 Akkuratova ul., Saint Petersburg, Russian Federation, 197341
3 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (4) , 419-433
Ponatinib Efficacy in Chronic Phase Chronic Myeloid Leukemia: Data from Three Centers in the Russian Federation
AIM. To assess the efficacy and tolerability of ponatinib in patients with the 1st chronic phase (CP) of chronic myeloid leukemia (CML) and with either prior tyrosine kinase inhibitor (ITK) resistance or the T315I mutation in the BCR::ABL1 gene. MATERIALS & METHODS. The study is based on the retrospective analysis of 99 CP CML patients treated with ponatinib in ≥ 2 therapy lines (83.8 % in the third and subsequent lines) as part of the clinical studies OPTIC, OPTIC-2L, and expanded access program in three medical institutions of the Russian Federation. The T315I mutation was identified in 31/96 patients (32.3 %). Most patients (86/99; 58.6 %) did not show complete hematologic response upon the start of ponatinib therapy, and 39/99 patients (39.4 %) did not achieve any cytogenetic response (CyR) on prior ITK therapy lines. RESULTS. On ponatinib therapy, the percentage of patients with complete CyR and molecular response 2 (CCyR/MR2) as well as major (MMR) and deep molecular response (DMR) was 55.4 %, 43.4 %, and 33.7 %, respectively. The median ponatinib therapy duration was 27.6 months (range 0.5–88.5 months). The probability of achieving CCyR/MR2 within 1 and 2 years of therapy was 45.9 % and 57.0 %, respectively. The median time before achieving CCyR/MR2 was 2.8 months (range 2.7–43.1 months), 38/51 patients (74.5 %) maintained CCyR/MR2 for 24 months. The number of patients with the T315I mutation and CCyR/MR2 was 12/31 (38.7 %), and the median time before achieving MR2 appeared to be comparable with that in the total cohort, i.e., 2.8 months (range 2.7–8.3 months). About half of patients achieved MMR and DMR by the 5th year of ponatinib therapy (57.7 % and 49.4 %, respectively). The median time before achieving MMR and DMR was 9.6 months (range 2.7–70.9 months) and 22.3 months (range 2.7–82.7 months), respectively. The multivariate regression analysis revealed favorable predictors of MR2 and MMR: BCR::ABL1 expression level ≤ 10 %, absence of mutations, and age ≤ 42 years at the start of ponatinib therapy. Rates of the 5-year OS, PFS, and EFS were 85.2 %, 86.6 %, and 34.3 %, respectively. CONCLUSION. Ponatinib demonstrated high efficacy both in patients with the T315I mutation and in heavily pre-treated patients. This study showed that baseline high level of BCR::ABL1 gene transcript or/and the absence of any CyR dramatically worsen long-term therapy outcomes. Another unfavorable prognostic factor is a failure to achieve CCyR/MR2 within the 1st year of ponatinib therapy, which calls for finding alternative treatment.
- 1 October 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (4) , 419-433
Open AccessPonatinib Efficacy in Chronic Phase Chronic Myeloid Leukemia: Data from Three Centers in the Russian Federation
AIM. To assess the efficacy and tolerability of ponatinib in patients with the 1st chronic phase (CP) of chronic myeloid leukemia (CML) and with either prior tyrosine kinase inhibitor (ITK) resistance or the T315I mutation in the BCR::ABL1 gene. MATERIALS & METHODS. The study is based on the retrospective analysis of 99 CP CML patients treated with ponatinib in ≥ 2 therapy lines (83.8 % in the third and subsequent lines) as part of the clinical studies OPTIC, OPTIC-2L, and expanded access program in three medical institutions of the Russian Federation. The T315I mutation was identified in 31/96 patients (32.3 %). Most patients (86/99; 58.6 %) did not show complete hematologic response upon the start of ponatinib therapy, and 39/99 patients (39.4 %) did not achieve any cytogenetic response (CyR) on prior ITK therapy lines. RESULTS. On ponatinib therapy, the percentage of patients with complete CyR and molecular response 2 (CCyR/MR2) as well as major (MMR) and deep molecular response (DMR) was 55.4 %, 43.4 %, and 33.7 %, respectively. The median ponatinib therapy duration was 27.6 months (range 0.5–88.5 months). The probability of achieving CCyR/MR2 within 1 and 2 years of therapy was 45.9 % and 57.0 %, respectively. The median time before achieving CCyR/MR2 was 2.8 months (range 2.7–43.1 months), 38/51 patients (74.5 %) maintained CCyR/MR2 for 24 months. The number of patients with the T315I mutation and CCyR/MR2 was 12/31 (38.7 %), and the median time before achieving MR2 appeared to be comparable with that in the total cohort, i.e., 2.8 months (range 2.7–8.3 months). About half of patients achieved MMR and DMR by the 5th year of ponatinib therapy (57.7 % and 49.4 %, respectively). The median time before achieving MMR and DMR was 9.6 months (range 2.7–70.9 months) and 22.3 months (range 2.7–82.7 months), respectively. The multivariate regression analysis revealed favorable predictors of MR2 and MMR: BCR::ABL1 expression level ≤ 10 %, absence of mutations, and age ≤ 42 years at the start of ponatinib therapy. Rates of the 5-year OS, PFS, and EFS were 85.2 %, 86.6 %, and 34.3 %, respectively. CONCLUSION. Ponatinib demonstrated high efficacy both in patients with the T315I mutation and in heavily pre-treated patients. This study showed that baseline high level of BCR::ABL1 gene transcript or/and the absence of any CyR dramatically worsen long-term therapy outcomes. Another unfavorable prognostic factor is a failure to achieve CCyR/MR2 within the 1st year of ponatinib therapy, which calls for finding alternative treatment.
- Open Access
- 1 April 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (2)
NK-Cell Receptor Repertoire in Chronic Myeloid Leukemia
BACKGROUND. Escape of leukemia cells from immune surveillance appears to be one of the most relevant areas in the study of resistance mechanisms in chronic myeloid leukemia (CML). AIM. To study the characteristics of the NK-cell immune response in patients with chronic phase (CP) CML on third-line therapy with tyrosine kinase inhibitors (TKIs) of the second generation. MATERIALS & METHODS. The study enrolled 40 CML CP patients receiving third-line therapy at the VA Almazov National Medical Research Center. The control group consisted of 20 healthy subjects (HS). The quantitative characteristics of NK- and TNK-cells as well as the expression of activating and inhibitory receptors on NK-cells were assessed using flow cytometry. KIR (Killer cell Immunoglobulin-like Receptors) haplotypes were analyzed by PCR and electrophoresis of PCR amplification products. RESULTS. Irrespective of treatment response, CML patients showed no significant differences regarding either the quantitative characteristics of NK- and TNK-cells or activating and inhibitory receptors on NK-cells. However, in the quantitative characteristics of inhibitory KIR alleles as well as in the expression of two activating KIR alleles (KIR2DS4 and KIR3DS1), significant differences were identified in HS vs. CML patients (p < 0.05). At the same time, the expression rate was similar in the groups with optimal response and therapy resistance (p = 0.25). There were also no significant differences in the rate of KIR haplotypes in HS and two groups of patients. In most CML patients as well as in HS, Bx haplotype of KIR was identified. The percentage of deaths was higher in the group with A haplotype (4/9; 45 %) vs. Bx haplotype (4/31; 13 %) (p = 0.008). The median progression-free survival (PFS) in the A haplotype subgroup was 76 (range 24–162) months vs. 69 (range 3–179) months in the Bx haplotype subgroup; the median overall survival (OS) was 69 (18–179) months vs. 76 (24–159) months, respectively. CONCLUSION. No significant differences were revealed in the expression of activating and inhibitory receptors on NK-cells in both groups of patients with response to TKI third-line therapy and therapy resistance compared to HS. This study demonstrated that NK-cell immune response had no effect on complete cytogenetic response. The results of the study suggest that the assessment of NK-cell immune response and KIR haplotypes cannot be regarded as a valuable tool for predicting the treatment efficacy in CML CP patients. However, due to heterogeneity of the groups under this study, further research is necessary to understand the prognostic value of KIR haplotypes in achieving response to therapy as well as their effect on OS and PFS.
- 1 April 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (2)
Open AccessNK-Cell Receptor Repertoire in Chronic Myeloid Leukemia
BACKGROUND. Escape of leukemia cells from immune surveillance appears to be one of the most relevant areas in the study of resistance mechanisms in chronic myeloid leukemia (CML). AIM. To study the characteristics of the NK-cell immune response in patients with chronic phase (CP) CML on third-line therapy with tyrosine kinase inhibitors (TKIs) of the second generation. MATERIALS & METHODS. The study enrolled 40 CML CP patients receiving third-line therapy at the VA Almazov National Medical Research Center. The control group consisted of 20 healthy subjects (HS). The quantitative characteristics of NK- and TNK-cells as well as the expression of activating and inhibitory receptors on NK-cells were assessed using flow cytometry. KIR (Killer cell Immunoglobulin-like Receptors) haplotypes were analyzed by PCR and electrophoresis of PCR amplification products. RESULTS. Irrespective of treatment response, CML patients showed no significant differences regarding either the quantitative characteristics of NK- and TNK-cells or activating and inhibitory receptors on NK-cells. However, in the quantitative characteristics of inhibitory KIR alleles as well as in the expression of two activating KIR alleles (KIR2DS4 and KIR3DS1), significant differences were identified in HS vs. CML patients (p < 0.05). At the same time, the expression rate was similar in the groups with optimal response and therapy resistance (p = 0.25). There were also no significant differences in the rate of KIR haplotypes in HS and two groups of patients. In most CML patients as well as in HS, Bx haplotype of KIR was identified. The percentage of deaths was higher in the group with A haplotype (4/9; 45 %) vs. Bx haplotype (4/31; 13 %) (p = 0.008). The median progression-free survival (PFS) in the A haplotype subgroup was 76 (range 24–162) months vs. 69 (range 3–179) months in the Bx haplotype subgroup; the median overall survival (OS) was 69 (18–179) months vs. 76 (24–159) months, respectively. CONCLUSION. No significant differences were revealed in the expression of activating and inhibitory receptors on NK-cells in both groups of patients with response to TKI third-line therapy and therapy resistance compared to HS. This study demonstrated that NK-cell immune response had no effect on complete cytogenetic response. The results of the study suggest that the assessment of NK-cell immune response and KIR haplotypes cannot be regarded as a valuable tool for predicting the treatment efficacy in CML CP patients. However, due to heterogeneity of the groups under this study, further research is necessary to understand the prognostic value of KIR haplotypes in achieving response to therapy as well as their effect on OS and PFS.
- Open Access
- 30 July 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 10,p. 94-102
Efficacy and safety of the second-generation tyrosine kinase inhibitor bosutinib in the treatment of chronic myeloid leukemia in the chronic phase
Introduction. ABL tyrosine kinase inhibitors (TKIs) have significantly improved the treatment outcomes for patients with chronic myeloid leukemia (CML). Bosutinib is a second-generation TKI that has demonstrated high efficacy and safety in clinical trials in firstand subsequent-line therapy of CML.Aim. To evaluate the long-term efficacy and safety of bosutinib in real-world clinical practice.Materials and methods. In our retrospective study all patients in the first chronic phase of CML who had ever received bosutinib therapy as their first, second, or third TKI were included. Only 4 patients (2 men) aged from 30 to 41 years received bosutinib as first TKI. Bosutinib was administered as second or third TKI to 19 patients (12 men) with a median age of 50 (31–71) and 17 patients (8 men) with a median age of 49.8 (21–70), respectively. Most patients had a long history of CML and most of them were resistant to previous TKIs.Results. All four patients who received bosutinib in the first-line achieved a complete hematological response (CHR), and three (75%) of them achieved a complete cytogenetic response (CCR) and a major molecular response (MMR). All 3 patients with MMR continued therapy for more than 16 years without significant adverse events. Among patients with bosutinib treatment after failure of imatinib or 2 TKIs, the CHR was achieved in most cases, and major cytogenetic response (MCR) was achieved in 7/19 (36.8%) and 6/17 (35.3%) cases. During the observation period, the median overall survival was not reached. There were few cases of bosutinib discontinuation due to drug intolerance. Long-term use of the drug did not lead to serious delayed side effects, including cardiovascular complications, associated with bosutinib therapy.Conclusions. Thus, in our group of patients with long-term observation, bosutinib showed not only a high frequency of achieving an optimal response in all lines of therapy in CP CML, but also the absence of severe remote complications, both hematological and non-hematological.
- 30 July 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 10,p. 94-102
Open AccessEfficacy and safety of the second-generation tyrosine kinase inhibitor bosutinib in the treatment of chronic myeloid leukemia in the chronic phase
Introduction. ABL tyrosine kinase inhibitors (TKIs) have significantly improved the treatment outcomes for patients with chronic myeloid leukemia (CML). Bosutinib is a second-generation TKI that has demonstrated high efficacy and safety in clinical trials in firstand subsequent-line therapy of CML.Aim. To evaluate the long-term efficacy and safety of bosutinib in real-world clinical practice.Materials and methods. In our retrospective study all patients in the first chronic phase of CML who had ever received bosutinib therapy as their first, second, or third TKI were included. Only 4 patients (2 men) aged from 30 to 41 years received bosutinib as first TKI. Bosutinib was administered as second or third TKI to 19 patients (12 men) with a median age of 50 (31–71) and 17 patients (8 men) with a median age of 49.8 (21–70), respectively. Most patients had a long history of CML and most of them were resistant to previous TKIs.Results. All four patients who received bosutinib in the first-line achieved a complete hematological response (CHR), and three (75%) of them achieved a complete cytogenetic response (CCR) and a major molecular response (MMR). All 3 patients with MMR continued therapy for more than 16 years without significant adverse events. Among patients with bosutinib treatment after failure of imatinib or 2 TKIs, the CHR was achieved in most cases, and major cytogenetic response (MCR) was achieved in 7/19 (36.8%) and 6/17 (35.3%) cases. During the observation period, the median overall survival was not reached. There were few cases of bosutinib discontinuation due to drug intolerance. Long-term use of the drug did not lead to serious delayed side effects, including cardiovascular complications, associated with bosutinib therapy.Conclusions. Thus, in our group of patients with long-term observation, bosutinib showed not only a high frequency of achieving an optimal response in all lines of therapy in CP CML, but also the absence of severe remote complications, both hematological and non-hematological.
- Open Access
- 22 May 2025
- Published by Publishing House ABV Press in Oncohematology
- Vol. 20 (2) , 53-66
Results of asciminib therapy as part of managed access program in patients with chronic myeloid leukemia with T315I mutation
Background. The most common mechanism of resistance to tyrosine kinase inhibitor (TKI) therapy in patients with chronic myeloid leukemia (CML) is point mutations in the BCR::ABL1 gene. Of particular importance is the T315I mutation, which causes insensitivity of leukemia cells to all ATp-competitive TKIs: imatinib and 2nd generation TKIs. Asciminib is the first drug of the STAMp inhibitor class that specifically interacts with the myristoyl-binding active site of the bCR::AbL1 molecule. In a phase I clinical trial, asciminib at a dose of 200 mg twice daily showed efficacy in the treatment of chronic phase (Cp) CML patients with T315I mutation. There are no data on the efficacy of asciminib therapy in patients with T315I mutation and additional chromosomal abnormalities (ACA) or advanced disease. The Russian part of the managed access program (MAp) has accumulated its own experience of using asciminib in CML patients with T315I mutation, including those with ACA and history of progression to the acceleration phase / blast crisis.Aim. To analyze the 3-year results of asciminib therapy as part of MAp in CML patients with T315I mutation.Materials and methods. In the MAp program to asciminib between October 2019 and January 2022 were included 26 CML patients with T315I mutation who were ineffective or intolerant to ATp-competitive TKIs therapy. Asciminib was administered at a dose of 200 mg twice daily. The efficacy and tolerability of asciminib therapy were assessed in accordance with national clinical guidelines and the 2020 European LeukemiaNet guidelines.At the time of asciminib therapy initiation, 19 (73 %) patients had Cp. four (15 %) patients had a history of acceleration phase (n = 3) and blast crisis (n = 1). four (15 %) patients had ACA immediately before the start of asciminib therapy, including a patient with a history of blast crisis. To analyze the asciminib therapy results, patients with a history of progression and / or ACA were combined into one group: 2Cp / Cp ACA+ (n = 7). More than half of patients (54 %) had previously received ponatinib.Results. The median duration of asciminib therapy was 31.6 (3.3–50) months. Of the 26 patients, 25 (96 %) are alive, one patient in the 2Cp / Cp ACA+ group died from progression of CML to myeloid blast crisis. In the total group, 14 patients (54 %) continued asciminib therapy, 12 (46 %) – discontinued treatment: most patients due to treatment failure (n = 9 (75 %)). In 3 patients (25 %), the reason for treatment discontinuation was allogeneic hematopoietic stem cell transplantation (all three achieved a complete cytogenetic response with asciminib therapy). No patients discontinued treatment due to toxicity. No new mutations, including asciminib resistance mutations, were detected during therapy.Progression-free survival and survival without therapy discontinuation at 3 years of follow-up in the total group were 92 and 58 %, respectively. when analyzing the Cp and 2Cp / Cp ACA+ groups, progression-free survival at 3 years of asciminib therapy was comparable. There was a trend toward decreased survival without therapy discontinuation in 2Cp / Cp ACA+ group (28 %) versus Cp group (63 %) (p = 0.0856).The probability of achieving a complete cytogenetic response / molecular response MR2 in all patients with T315I mutation by the 3rd year of asciminib treatment was 59 %, in the Cp and 2Cp / Cp ACA+ groups – 47 and 80 %, respectively; no significant difference were found between the groups (p = 0.08). The probability of achieving a major molecular response (MMR) in the total group by the 3rd year of asciminib treatment was 42 %; the probability of achieving MMR in the Cp and 2Cp / Cp ACA+ groups was 44 and 33 %, respectively; no significant difference were found between the groups (p = 0.6).In univariate analysis, significant favorable factors for achieving MMR were the molecular response at the start of asciminib therapy ≤10 %, the best molecular response in prior TKI therapy ≤1 %, and the absence of prior ponatinib treatment. In multivariate analysis, a history of ponatinib therapy was an independent significant factor for achieving MMR with asciminib therapy (p = 0.02; hazard ratio 12.08).Conclusion. The therapy results of patients in initially unfavorable 2Cp / Cp ACA+ group were comparable with Cp group in terms of both survival rates and probability of achieving responses. However, given the small number of patients in our cohort, the asciminib efficacy in patients with T315I+ CML with ACA and a history of progression requires further investigation. A factor that significantly reduced the probability of achieving MMR during asciminib treatment was a history of ponatinib therapy.
- 22 May 2025
- Published by Publishing House ABV Press in Oncohematology
- Vol. 20 (2) , 53-66
Open AccessResults of asciminib therapy as part of managed access program in patients with chronic myeloid leukemia with T315I mutation
Background. The most common mechanism of resistance to tyrosine kinase inhibitor (TKI) therapy in patients with chronic myeloid leukemia (CML) is point mutations in the BCR::ABL1 gene. Of particular importance is the T315I mutation, which causes insensitivity of leukemia cells to all ATp-competitive TKIs: imatinib and 2nd generation TKIs. Asciminib is the first drug of the STAMp inhibitor class that specifically interacts with the myristoyl-binding active site of the bCR::AbL1 molecule. In a phase I clinical trial, asciminib at a dose of 200 mg twice daily showed efficacy in the treatment of chronic phase (Cp) CML patients with T315I mutation. There are no data on the efficacy of asciminib therapy in patients with T315I mutation and additional chromosomal abnormalities (ACA) or advanced disease. The Russian part of the managed access program (MAp) has accumulated its own experience of using asciminib in CML patients with T315I mutation, including those with ACA and history of progression to the acceleration phase / blast crisis.Aim. To analyze the 3-year results of asciminib therapy as part of MAp in CML patients with T315I mutation.Materials and methods. In the MAp program to asciminib between October 2019 and January 2022 were included 26 CML patients with T315I mutation who were ineffective or intolerant to ATp-competitive TKIs therapy. Asciminib was administered at a dose of 200 mg twice daily. The efficacy and tolerability of asciminib therapy were assessed in accordance with national clinical guidelines and the 2020 European LeukemiaNet guidelines.At the time of asciminib therapy initiation, 19 (73 %) patients had Cp. four (15 %) patients had a history of acceleration phase (n = 3) and blast crisis (n = 1). four (15 %) patients had ACA immediately before the start of asciminib therapy, including a patient with a history of blast crisis. To analyze the asciminib therapy results, patients with a history of progression and / or ACA were combined into one group: 2Cp / Cp ACA+ (n = 7). More than half of patients (54 %) had previously received ponatinib.Results. The median duration of asciminib therapy was 31.6 (3.3–50) months. Of the 26 patients, 25 (96 %) are alive, one patient in the 2Cp / Cp ACA+ group died from progression of CML to myeloid blast crisis. In the total group, 14 patients (54 %) continued asciminib therapy, 12 (46 %) – discontinued treatment: most patients due to treatment failure (n = 9 (75 %)). In 3 patients (25 %), the reason for treatment discontinuation was allogeneic hematopoietic stem cell transplantation (all three achieved a complete cytogenetic response with asciminib therapy). No patients discontinued treatment due to toxicity. No new mutations, including asciminib resistance mutations, were detected during therapy.Progression-free survival and survival without therapy discontinuation at 3 years of follow-up in the total group were 92 and 58 %, respectively. when analyzing the Cp and 2Cp / Cp ACA+ groups, progression-free survival at 3 years of asciminib therapy was comparable. There was a trend toward decreased survival without therapy discontinuation in 2Cp / Cp ACA+ group (28 %) versus Cp group (63 %) (p = 0.0856).The probability of achieving a complete cytogenetic response / molecular response MR2 in all patients with T315I mutation by the 3rd year of asciminib treatment was 59 %, in the Cp and 2Cp / Cp ACA+ groups – 47 and 80 %, respectively; no significant difference were found between the groups (p = 0.08). The probability of achieving a major molecular response (MMR) in the total group by the 3rd year of asciminib treatment was 42 %; the probability of achieving MMR in the Cp and 2Cp / Cp ACA+ groups was 44 and 33 %, respectively; no significant difference were found between the groups (p = 0.6).In univariate analysis, significant favorable factors for achieving MMR were the molecular response at the start of asciminib therapy ≤10 %, the best molecular response in prior TKI therapy ≤1 %, and the absence of prior ponatinib treatment. In multivariate analysis, a history of ponatinib therapy was an independent significant factor for achieving MMR with asciminib therapy (p = 0.02; hazard ratio 12.08).Conclusion. The therapy results of patients in initially unfavorable 2Cp / Cp ACA+ group were comparable with Cp group in terms of both survival rates and probability of achieving responses. However, given the small number of patients in our cohort, the asciminib efficacy in patients with T315I+ CML with ACA and a history of progression requires further investigation. A factor that significantly reduced the probability of achieving MMR during asciminib treatment was a history of ponatinib therapy.
- Open Access
- 30 August 2023
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 23, S344
CML-480 The Clonality of Myeloid-Derived Suppressor Cells in Chronic Myeloid Leukemia Patients
- 30 August 2023
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 23, S344
Open AccessCML-480 The Clonality of Myeloid-Derived Suppressor Cells in Chronic Myeloid Leukemia Patients
- Open Access
- 30 August 2023
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 23, S179
POSTER: CML-449 JAK2-Unmutated Erythrocytosis in Chronic Phase Myeloid Leukemia (CP-CML) During Tyrosine Kinase Inhibitor (TKI) Treatment
- 30 August 2023
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 23, S179
Open AccessPOSTER: CML-449 JAK2-Unmutated Erythrocytosis in Chronic Phase Myeloid Leukemia (CP-CML) During Tyrosine Kinase Inhibitor (TKI) Treatment
- Open Access
- 30 August 2023
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 23, S343-S344
CML-449 JAK2-Unmutated Erythrocytosis in Chronic Phase Myeloid Leukemia (CP-CML) During Tyrosine Kinase Inhibitor (TKI) Treatment
- 30 August 2023
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 23, S343-S344
Open AccessCML-449 JAK2-Unmutated Erythrocytosis in Chronic Phase Myeloid Leukemia (CP-CML) During Tyrosine Kinase Inhibitor (TKI) Treatment
- Open Access
- 30 August 2023
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 23, S177
POSTER: CML-480 The Clonality of Myeloid-Derived Suppressor Cells in Chronic Myeloid Leukemia Patients
- 30 August 2023
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 23, S177
Open AccessPOSTER: CML-480 The Clonality of Myeloid-Derived Suppressor Cells in Chronic Myeloid Leukemia Patients